NCT02220985 · ADVERSE EVENTS

Adverse events

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD · Source last updated 2026-06-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Serious and other adverse events were reported from pre-transplant conditioning through day 100 post-transplant. All-cause mortality (including both relapse and non-relapse mortality) was assessed for up to 5 years post-transplant.
Other-event reporting threshold: 5%

Only grades 3-5 non-hematologic adverse events were captured.

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Arm A (MRD / High Intensity Conditioning) HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2. TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0. GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.	21 / 21	6 / 21	5 / 21
Arm B (MRD / Low Intensity Conditioning) LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1. TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0. GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator.	17 / 20	8 / 20	4 / 20
Arm C (MUD / High Intensity Conditioning) HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2. TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0. GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.	18 / 18	6 / 18	4 / 18
Arm D (MUD / Low Intensity Conditioning) LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1. TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0. GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator.	15 / 18	8 / 18	4 / 18

Group identifiers: EG000: Arm A (MRD / High Intensity Conditioning) · EG001: Arm B (MRD / Low Intensity Conditioning) · EG002: Arm C (MUD / High Intensity Conditioning) · EG003: Arm D (MUD / Low Intensity Conditioning)

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
1
num At Risk
21
num Events
1
group Id
EG001
num Affected
0
num At Risk
20
num Events
0
group Id
EG002
num Affected
0
num At Risk
18
num Events
0
group Id
EG003
num Affected
0
num At Risk
18
num Events
0
term
Heart Failure
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
num Events
0
group Id
EG001
num Affected
0
num At Risk
20
num Events
0
group Id
EG002
num Affected
1
num At Risk
18
num Events
1
group Id
EG003
num Affected
1
num At Risk
18
num Events
1
term
Abdominal pain
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
num Events
0
group Id
EG001
num Affected
2
num At Risk
20
num Events
3
group Id
EG002
num Affected
3
num At Risk
18
num Events
3
group Id
EG003
num Affected
1
num At Risk
18
num Events
1
term
Diarrhea
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
num Events
0
group Id
EG001
num Affected
0
num At Risk
20
num Events
0
group Id
EG002
num Affected
1
num At Risk
18
num Events
1
group Id
EG003
num Affected
0
num At Risk
18
num Events
0
term
Esophagitis
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
num Events
0
group Id
EG001
num Affected
0
num At Risk
20
num Events
0
group Id
EG002
num Affected
1
num At Risk
18
num Events
1
group Id
EG003
num Affected
0
num At Risk
18
num Events
0
term
Gastrointestinal Pain
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
num Events
0
group Id
EG001
num Affected
0
num At Risk
20
num Events
0
group Id
EG002
num Affected
0
num At Risk
18
num Events
0
group Id
EG003
num Affected
1
num At Risk
18
num Events
1
term
Gastroparesis
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
17
num At Risk
21
num Events
17
group Id
EG001
num Affected
4
num At Risk
20
num Events
4
group Id
EG002
num Affected
18
num At Risk
18
num Events
18
group Id
EG003
num Affected
8
num At Risk
18
num Events
8
term
Mucositis oral
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
3
num At Risk
21
num Events
3
group Id
EG001
num Affected
5
num At Risk
20
num Events
5
group Id
EG002
num Affected
2
num At Risk
18
num Events
2
group Id
EG003
num Affected
4
num At Risk
18
num Events
5
term
Nausea
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
1
num At Risk
21
num Events
1
group Id
EG001
num Affected
0
num At Risk
20
num Events
0
group Id
EG002
num Affected
0
num At Risk
18
num Events
0
group Id
EG003
num Affected
0
num At Risk
18
num Events
0
term
Typhlitis
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
num Events
0
group Id
EG001
num Affected
0
num At Risk
20
num Events
0
group Id
EG002
num Affected
1
num At Risk
18
num Events
1
group Id
EG003
num Affected
0
num At Risk
18
num Events
0
term
Vomiting
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
1
num At Risk
21
num Events
1
group Id
EG001
num Affected
0
num At Risk
20
num Events
0
group Id
EG002
num Affected
2
num At Risk
18
num Events
3
group Id
EG003
num Affected
0
num At Risk
18
num Events
0
term
Fever
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
num Events
0
group Id
EG001
num Affected
1
num At Risk
20
num Events
1
group Id
EG002
num Affected
2
num At Risk
18
num Events
2
group Id
EG003
num Affected
0
num At Risk
18
num Events
0
term
Pain

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
group Id
EG001
num Affected
3
num At Risk
20
num Events
3
group Id
EG002
num Affected
0
num At Risk
18
group Id
EG003
num Affected
2
num At Risk
18
num Events
2
term
Diarrhea
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Immune system disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
group Id
EG001
num Affected
0
num At Risk
20
group Id
EG002
num Affected
0
num At Risk
18
group Id
EG003
num Affected
1
num At Risk
18
num Events
1
term
Cytokine release syndrome
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
group Id
EG001
num Affected
0
num At Risk
20
group Id
EG002
num Affected
1
num At Risk
18
num Events
1
group Id
EG003
num Affected
2
num At Risk
18
num Events
2
term
Infections and infestations, other
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Metabolism and nutrition disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
2
num At Risk
21
num Events
2
group Id
EG001
num Affected
2
num At Risk
20
num Events
2
group Id
EG002
num Affected
1
num At Risk
18
num Events
1
group Id
EG003
num Affected
0
num At Risk
18
term
Hyperglycemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Metabolism and nutrition disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
1
num At Risk
21
num Events
1
group Id
EG001
num Affected
0
num At Risk
20
group Id
EG002
num Affected
0
num At Risk
18
group Id
EG003
num Affected
1
num At Risk
18
num Events
1
term
Hypermagnesemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Metabolism and nutrition disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
group Id
EG001
num Affected
0
num At Risk
20
group Id
EG002
num Affected
0
num At Risk
18
group Id
EG003
num Affected
2
num At Risk
18
num Events
2
term
Hypokalemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Metabolism and nutrition disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
2
num At Risk
21
num Events
2
group Id
EG001
num Affected
1
num At Risk
20
num Events
1
group Id
EG002
num Affected
0
num At Risk
18
group Id
EG003
num Affected
1
num At Risk
18
num Events
1
term
Hyponatremia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Metabolism and nutrition disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
1
num At Risk
21
num Events
1
group Id
EG001
num Affected
2
num At Risk
20
num Events
2
group Id
EG002
num Affected
1
num At Risk
18
num Events
1
group Id
EG003
num Affected
1
num At Risk
18
num Events
1
term
Hypophosphatemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Nervous system disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
group Id
EG001
num Affected
2
num At Risk
20
num Events
2
group Id
EG002
num Affected
2
num At Risk
18
num Events
3
group Id
EG003
num Affected
1
num At Risk
18
num Events
1
term
Syncope
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Skin and subcutaneous tissue disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
group Id
EG001
num Affected
0
num At Risk
20
group Id
EG002
num Affected
3
num At Risk
18
num Events
3
group Id
EG003
num Affected
1
num At Risk
18
num Events
1
term
Rash maculo-papular
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Vascular disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
2
num At Risk
21
num Events
2
group Id
EG001
num Affected
0
num At Risk
20
group Id
EG002
num Affected
2
num At Risk
18
num Events
2
group Id
EG003
num Affected
3
num At Risk
18
num Events
3
term
Hypertension

Complete source fields

description

Only grades 3-5 non-hematologic adverse events were captured.

event Groups

deaths Num Affected
5
deaths Num At Risk
21
description
HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2. TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0. GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.
id
EG000
other Num Affected
6
other Num At Risk
21
serious Num Affected
21
serious Num At Risk
21
title
Arm A (MRD / High Intensity Conditioning)
deaths Num Affected
4
deaths Num At Risk
20
description
LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1. TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0. GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator.
id
EG001
other Num Affected
8
other Num At Risk
20
serious Num Affected
17
serious Num At Risk
20
title
Arm B (MRD / Low Intensity Conditioning)
deaths Num Affected
4
deaths Num At Risk
18
description
HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2. TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0. GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.
id
EG002
other Num Affected
6
other Num At Risk
18
serious Num Affected
18
serious Num At Risk
18
title
Arm C (MUD / High Intensity Conditioning)
deaths Num Affected
4
deaths Num At Risk
18
description
LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1. TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0. GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator.
id
EG003
other Num Affected
8
other Num At Risk
18
serious Num Affected
15
serious Num At Risk
18
title
Arm D (MUD / Low Intensity Conditioning)

frequency Threshold

other Events

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
group Id
EG001
num Affected
3
num At Risk
20
num Events
3
group Id
EG002
num Affected
0
num At Risk
18
group Id
EG003
num Affected
2
num At Risk
18
num Events
2
term
Diarrhea
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Immune system disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
group Id
EG001
num Affected
0
num At Risk
20
group Id
EG002
num Affected
0
num At Risk
18
group Id
EG003
num Affected
1
num At Risk
18
num Events
1
term
Cytokine release syndrome
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
group Id
EG001
num Affected
0
num At Risk
20
group Id
EG002
num Affected
1
num At Risk
18
num Events
1
group Id
EG003
num Affected
2
num At Risk
18
num Events
2
term
Infections and infestations, other
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Metabolism and nutrition disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
2
num At Risk
21
num Events
2
group Id
EG001
num Affected
2
num At Risk
20
num Events
2
group Id
EG002
num Affected
1
num At Risk
18
num Events
1
group Id
EG003
num Affected
0
num At Risk
18
term
Hyperglycemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Metabolism and nutrition disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
1
num At Risk
21
num Events
1
group Id
EG001
num Affected
0
num At Risk
20
group Id
EG002
num Affected
0
num At Risk
18
group Id
EG003
num Affected
1
num At Risk
18
num Events
1
term
Hypermagnesemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Metabolism and nutrition disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
group Id
EG001
num Affected
0
num At Risk
20
group Id
EG002
num Affected
0
num At Risk
18
group Id
EG003
num Affected
2
num At Risk
18
num Events
2
term
Hypokalemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Metabolism and nutrition disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
2
num At Risk
21
num Events
2
group Id
EG001
num Affected
1
num At Risk
20
num Events
1
group Id
EG002
num Affected
0
num At Risk
18
group Id
EG003
num Affected
1
num At Risk
18
num Events
1
term
Hyponatremia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Metabolism and nutrition disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
1
num At Risk
21
num Events
1
group Id
EG001
num Affected
2
num At Risk
20
num Events
2
group Id
EG002
num Affected
1
num At Risk
18
num Events
1
group Id
EG003
num Affected
1
num At Risk
18
num Events
1
term
Hypophosphatemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Nervous system disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
group Id
EG001
num Affected
2
num At Risk
20
num Events
2
group Id
EG002
num Affected
2
num At Risk
18
num Events
3
group Id
EG003
num Affected
1
num At Risk
18
num Events
1
term
Syncope
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Skin and subcutaneous tissue disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
group Id
EG001
num Affected
0
num At Risk
20
group Id
EG002
num Affected
3
num At Risk
18
num Events
3
group Id
EG003
num Affected
1
num At Risk
18
num Events
1
term
Rash maculo-papular
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Vascular disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
2
num At Risk
21
num Events
2
group Id
EG001
num Affected
0
num At Risk
20
group Id
EG002
num Affected
2
num At Risk
18
num Events
2
group Id
EG003
num Affected
3
num At Risk
18
num Events
3
term
Hypertension

serious Events

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
1
num At Risk
21
num Events
1
group Id
EG001
num Affected
0
num At Risk
20
num Events
0
group Id
EG002
num Affected
0
num At Risk
18
num Events
0
group Id
EG003
num Affected
0
num At Risk
18
num Events
0
term
Heart Failure
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
num Events
0
group Id
EG001
num Affected
0
num At Risk
20
num Events
0
group Id
EG002
num Affected
1
num At Risk
18
num Events
1
group Id
EG003
num Affected
1
num At Risk
18
num Events
1
term
Abdominal pain
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
num Events
0
group Id
EG001
num Affected
2
num At Risk
20
num Events
3
group Id
EG002
num Affected
3
num At Risk
18
num Events
3
group Id
EG003
num Affected
1
num At Risk
18
num Events
1
term
Diarrhea
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
num Events
0
group Id
EG001
num Affected
0
num At Risk
20
num Events
0
group Id
EG002
num Affected
1
num At Risk
18
num Events
1
group Id
EG003
num Affected
0
num At Risk
18
num Events
0
term
Esophagitis
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
num Events
0
group Id
EG001
num Affected
0
num At Risk
20
num Events
0
group Id
EG002
num Affected
1
num At Risk
18
num Events
1
group Id
EG003
num Affected
0
num At Risk
18
num Events
0
term
Gastrointestinal Pain
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
num Events
0
group Id
EG001
num Affected
0
num At Risk
20
num Events
0
group Id
EG002
num Affected
0
num At Risk
18
num Events
0
group Id
EG003
num Affected
1
num At Risk
18
num Events
1
term
Gastroparesis
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
17
num At Risk
21
num Events
17
group Id
EG001
num Affected
4
num At Risk
20
num Events
4
group Id
EG002
num Affected
18
num At Risk
18
num Events
18
group Id
EG003
num Affected
8
num At Risk
18
num Events
8
term
Mucositis oral
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
3
num At Risk
21
num Events
3
group Id
EG001
num Affected
5
num At Risk
20
num Events
5
group Id
EG002
num Affected
2
num At Risk
18
num Events
2
group Id
EG003
num Affected
4
num At Risk
18
num Events
5
term
Nausea
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
1
num At Risk
21
num Events
1
group Id
EG001
num Affected
0
num At Risk
20
num Events
0
group Id
EG002
num Affected
0
num At Risk
18
num Events
0
group Id
EG003
num Affected
0
num At Risk
18
num Events
0
term
Typhlitis
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
num Events
0
group Id
EG001
num Affected
0
num At Risk
20
num Events
0
group Id
EG002
num Affected
1
num At Risk
18
num Events
1
group Id
EG003
num Affected
0
num At Risk
18
num Events
0
term
Vomiting
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
1
num At Risk
21
num Events
1
group Id
EG001
num Affected
0
num At Risk
20
num Events
0
group Id
EG002
num Affected
2
num At Risk
18
num Events
3
group Id
EG003
num Affected
0
num At Risk
18
num Events
0
term
Fever
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
CTCAE v4
stats
group Id
EG000
num Affected
0
num At Risk
21
num Events
0
group Id
EG001
num Affected
1
num At Risk
20
num Events
1
group Id
EG002
num Affected
2
num At Risk
18
num Events
2
group Id
EG003
num Affected
0
num At Risk
18
num Events
0
term
Pain

time Frame

Serious and other adverse events were reported from pre-transplant conditioning through day 100 post-transplant. All-cause mortality (including both relapse and non-relapse mortality) was assessed for up to 5 years post-transplant.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice